Cardiol Therapeutics' Presents Phase II MAvERIC-Pilot Clinical Results In Recurrent Pericarditis Presented At The AHA Scientific Sessions 2024; Marked And Rapid Reductions In Both Pericarditis Pain And Inflammation Maintained Throughout The 26-Week Study
Reported Sunday, Alnylam Reported Interim Phase 1 Results For Nucresiran (ALN-TTRsc04), Demonstrating Rapid And Sustained TTR Reduction Lasting Six Months After A Single Dose
Watching Incyte; Traders Circulate Research Report From Unemon Suggesting Novartis Emerges As The Ideal Acquirer, Says "Would Not Be Surprised To See A $105-$110 Deal In The Coming Weeks"
Ideal Power Inc. (IPWR) Q3 2024 Earnings Call Transcript Summary
Bitcoin, Ethereum, Dogecoin Turn Red, Trader Marks 'Ideal Support Level At $81,500'
Ideal Power Shares Are Trading Lower. The Company Reported Q3 Financial Results.